Olink®Part of Thermo Fisher Scientific
Powerful, NGS-based proteomics - effortlessly uncover meaningful insights
A unique combination of specificity and scalability enables high-throughput, multiplex protein biomarker analysis.
Next-generation high-throughput proteomics empowers genetically-informed assessment of protein causality and the confident identification of novel drug targets.
Join the growing global community and consortia of Olink users to empower your biomarker discovery.
Over 2,800 and growing rapidly – covering all major disease areas
Your source for Olink’s terms, privacy policies, and compliance details
Filters
European Journal of Heart Failure, 2023Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials
Ferreira J., Butler J., Anker S. et al.
Olink Explore 3072/384
eBioMedicine, 2023Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial
Zhang X., Irajizad E., Hoffman K. et al.
Olink Target 96
Scientific Reports, 2023Using trials of caloric restriction and bariatric surgery to explore the effects of body mass index on the circulating proteome
Goudswaard L., Smith M., Hughes D. et al.
Cancers, 2023Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor
Stensgaard S., Thomsen A., Helstrup S. et al.
Nature Communications, 2023Plasma proteomic profiles predict individual future health risk
You J., Guo Y., Zhang Y. et al.
Circulation: Genomic and Precision Medicine, 2023Plasma Protein Profiling of Incident Cardiovascular Diseases: A Multisample Evaluation
Lind L., Titova O., Zeng R. et al.
ESC Heart Failure, 2023Sex‐specific cardiovascular protein levels and their link with clinical outcome in heart failure
de Bakker M., Loncq de Jong M., Petersen T. et al.
Journal of Thrombosis and Haemostasis, 2023Proteomic insights into modifiable risk of venous thromboembolism and cardiovascular comorbidities
Yuan S., Xu F., Zhang H. et al.
Pediatric Research, 2023Antisecretory factor in breastmilk is associated with reduced incidence of sepsis in preterm infants
Gustafsson A., Johansson E., Henckel E. et al.
Nature Communications, 2023Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation
Mälarstig A., Grassmann F., Dahl L. et al.
iScience, 2023Hospital-treated prevalent infections, the plasma proteome and incident dementia among UK older adults
Beydoun M., Beydoun H., Noren Hooten N. et al.
Frontiers in Immunology, 2023Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay
Kmezic I., Gustafsson R., Fink K. et al.
iScience, 2023Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion
Moaddel R., Farmer C., Yavi M. et al.
Brain, 2023Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains
Quesnel M., Labonté A., Picard C. et al.
Scientific Reports, 2023Galectin-4 is associated with diabetes and obesity in a heart failure population
Dieden A., Gudmundsson P., Korduner J. et al.
Frontiers in Immunology, 2023Olink proteomics analysis uncovers the landscape of inflammation-related proteins in patients with acute compartment syndrome
Wang T., Yang S., Long Y. et al.
Molecular Neurobiology, 2023Causal Association of Cytokines and Growth Factors with Stroke and Its Subtypes: a Mendelian Randomization Study
Chen G., Lin T., Wu M. et al.
Scientific Reports, 2023Markers of inflammation predict survival in newly diagnosed cirrhosis: a prospective registry study
Mynster Kronborg T., Webel H., O’Connell M. et al.
Journal of Applied Physiology, 2023Type 2 diabetes exacerbates changes in blood pressure-independent arterial stiffness: cross-sectional and longitudinal evidence from the SUMMIT study
Aizawa K., Gates P., Mawson D. et al.
Translational Neurodegeneration, 2023A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
Faridar A., Eid A., Thome A. et al.
Olink Target 48
2821 publications
Items per page
1241-1260 of 2821 publications